Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Horizon Therapeutics Public Ltd CoHZNP · Entity 109157 | EVP, Commercial Dev & Strategy | October 25, 2017 | October 26, 2017 |
| Sagimet Biosciences Inc.SGMT · Entity 5273 | Director · President & CEO | July 20, 2026 | July 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Horizon Therapeutics Public Ltd Co
Report date October 25, 2017 · Filed October 26, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 9,239 |
Reported balance
After 2017-10-25 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-10-25 · Exercise / conversion · Acquired 7,953 · Balance 9,239 F1: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F2: Includes 1,286 ordinary shares of the Issuer acquired by the reporting person on June 1, 2017 pursuant to an employee stock purchase program. |
| Ordinary SharesSEC Table I · non-derivative | Direct | 5,089 |
Reported balance
After 2017-10-25 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2017-10-25 · Tax withholding · Disposed 4,150 · Balance 5,089 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 23,860 |
Reported balance
After 2017-10-25 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-10-25 · Exercise / conversion · Disposed 7,953 · Balance 23,860 F1: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F3: On October 25, 2016, the reporting person was granted an aggregate of 31,813 restricted stock units. The restricted stock units vest in four equal annual installments beginning on October 25, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer.
F2: Includes 1,286 ordinary shares of the Issuer acquired by the reporting person on June 1, 2017 pursuant to an employee stock purchase program.
F3: On October 25, 2016, the reporting person was granted an aggregate of 31,813 restricted stock units. The restricted stock units vest in four equal annual installments beginning on October 25, 2017.
Sagimet Biosciences Inc.
Report date July 20, 2026 · Filed July 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Series A Common StockSEC Table I · non-derivative | Direct | 741,570 |
Reported balance
After 2026-07-20 transaction · row 1
1 source rowRow 1 · 2026-07-20 · Sale · Disposed 64,051 · Balance 741,570 F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.76 to $7.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.76 to $7.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Raptor Pharmaceutical Corp
Report date October 24, 2016 · Filed October 26, 2016
Section 16 reporting ended · disclosed 2016-10-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2016-10-25 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2016-10-24 · Other · Disposed 8,934 · Balance 28,939 F1: Shares tendered in connection with an offer to purchase all of the issued and outstanding shares of common stock of Raptor Pharmaceutical Corp. ("Raptor"), par value $0.001 per share, for an amount of $9.00 per share in cash, without interest and less any applicable withholding taxes, commenced pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 12, 2016, by and among Raptor, Horizon Pharma plc, a public limited company organized under the laws of Ireland ("Parent") and Misneach Corporation, a Delaware corporation and an indirect wholly owned subsidiary of Parent. Row 2 · 2016-10-25 · Disposition to issuer · Disposed 28,939 · Balance 0 F2: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding restricted stock unit was accelerated in full and cancelled in exchange for the right to receive $9.00 per share in cash, without interest and less any required withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.74 · Expires 2026-02-09 | Direct | 0 |
Reported balance
After 2016-10-25 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2016-10-25 · Disposition to issuer · Disposed 93,784 · Balance 0 F3: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares tendered in connection with an offer to purchase all of the issued and outstanding shares of common stock of Raptor Pharmaceutical Corp. ("Raptor"), par value $0.001 per share, for an amount of $9.00 per share in cash, without interest and less any applicable withholding taxes, commenced pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 12, 2016, by and among Raptor, Horizon Pharma plc, a public limited company organized under the laws of Ireland ("Parent") and Misneach Corporation, a Delaware corporation and an indirect wholly owned subsidiary of Parent.
F2: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding restricted stock unit was accelerated in full and cancelled in exchange for the right to receive $9.00 per share in cash, without interest and less any required withholding taxes.
F3: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 20, 2026 Filed Jul 22, 2026 20:05 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | SaleSeries A Common Stock | 64,051 | $7.76 | $497,067.79 |
DisclosureSEC source: 0001193125-26-312397 · ownership.xml · nonDerivative · entry 1 Happel David · CIK 0001623567 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 741,570 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.76 to $7.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 28, 2026 Filed Jun 2, 2026 01:13 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0001104659-26-069121 · tm2616578-1_4seq1.xml · derivative · entry 1 Happel David · CIK 0001623567 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Series A Common Stock · 300,000 shares Expires 2036-05-27 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following May 28, 2026, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| February 19, 2026 Filed Feb 20, 2026 21:41 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 256,000 | $0.00 Strike: $5.38 | $0.00 |
DisclosureSEC source: 0001104659-26-018193 · tm266959-2_4seq1.xml · derivative · entry 2 Happel David · CIK 0001623567 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 256,000 Underlying: Series A Common Stock · 256,000 shares Expires 2036-02-18 F2 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| February 19, 2026 Filed Feb 20, 2026 21:41 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantSeries A Common Stock | 128,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-018193 · tm266959-2_4seq1.xml · nonDerivative · entry 1 Happel David · CIK 0001623567 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 805,621 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. The RSUs shall vest over four equal annual installments following February 19, 2026, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 21:08 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | SaleSeries A Common Stock | 12,101 | $5.36 | $64,864.99 |
DisclosureSEC source: 0001104659-26-014283 · tm266207-4_4seq1.xml · nonDerivative · entry 1 Happel David · CIK 0001623567 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 677,621 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. Read SEC document |
| July 21, 2025 Filed Jul 23, 2025 20:16 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | SaleSeries A Common Stock | 65,478 | $9.13 | $598,115.34 |
DisclosureSEC source: 0001104659-25-070017 · tm2521574-3_4seq1.xml · nonDerivative · entry 1 Happel David · CIK 0001623567 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 689,722 F1 · kind: Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person. Read SEC document |
| February 06, 2025 Filed Feb 7, 2025 21:43 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 472,000 | $0.00 Strike: $4.71 | $0.00 |
DisclosureSEC source: 0001104659-25-010587 · tm255919-3_4seq1.xml · derivative · entry 2 Happel David · CIK 0001623567 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 472,000 Underlying: Series A Common Stock · 472,000 shares Expires 2035-02-05 F2 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable over forty-eight equal monthly installments following February 6, 2025, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| February 06, 2025 Filed Feb 7, 2025 21:43 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantSeries A Common Stock | 116,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-010587 · tm255919-3_4seq1.xml · nonDerivative · entry 1 Happel David · CIK 0001623567 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 755,200 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. The RSUs shall vest over four equal annual installments following February 6, 2025, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| March 26, 2024 Filed Mar 28, 2024 20:08 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | PurchaseSeries A Common Stock | 12,100 | $5.27 | $63,730.70 |
DisclosureSEC source: 0001104659-24-040517 · tm2410115-1_4seq1.xml · nonDerivative · entry 1 Happel David · CIK 0001623567 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 639,200 F1 · price: Reflects the weighted average price. The shares were purchased in multiple transactions at prices ranging from $5.24 per share to $5.2999 per share. The Reporting Person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each price. Read SEC document |
| December 07, 2023 Filed Dec 8, 2023 21:05 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | PurchaseSeries A Common Stock | 1,600 | $4.10 | $6,560.00 |
DisclosureSEC source: 0001104659-23-124678 · tm2332520-1_4seq1.xml · nonDerivative · entry 1 Happel David · CIK 0001623567 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 627,100 F1 · price: Reflects the weighted average price. The shares were purchased in multiple transactions at prices ranging from $4.02 per share to $4.16 per share. The Reporting Person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each price. Read SEC document |
| November 17, 2023 Filed Nov 21, 2023 21:21 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantSeries A Common Stock | 624,910 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-120372 · tm2331048-1_4seq1.xml · nonDerivative · entry 1 Happel David · CIK 0001623567 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 625,500 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Series A Common Stock upon vesting and settlement. 25% of the RSUs shall vest on July 18, 2024, with the remainder vesting in three equal annual installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| November 16, 2023 Filed Nov 21, 2023 02:59 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | PurchaseSeries A Common Stock | 590 | $2.35 | $1,386.50 |
DisclosureSEC source: 0001104659-23-120027 · tm2331267-1_4seq1.xml · nonDerivative · entry 1 Happel David · CIK 0001623567 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 590 F1 · price: Reflects the weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.31 per share to $2.40 per share. The Reporting Person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each price. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:15 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | GrantStock Option (Right to Buy) · Derivative | 1,011,826 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001104659-23-082722 · tm2321276-14_4seq1.xml · derivative · entry 2 Happel David · CIK 0001623567 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,011,826 Underlying: Series A Common Stock · 1,011,826 shares Expires 2032-10-16 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2 · derivative.exercise_date: 25% of the shares underlying this option shall vest and become exercisable on October 17, 2023, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| July 18, 2023 Filed Jul 20, 2023 20:15 UTC | Sagimet Biosciences Inc. SGMT · Entity 5273 | Disposition to issuerStock Option (Right to Buy) · Derivative | 1,011,826 | $0.00 Strike: $7.15 | $0.00 |
DisclosureSEC source: 0001104659-23-082722 · tm2321276-14_4seq1.xml · derivative · entry 1 Happel David · CIK 0001623567 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,011,826 shares Expires 2032-10-16 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2 · derivative.exercise_date: 25% of the shares underlying this option shall vest and become exercisable on October 17, 2023, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| October 25, 2017 Filed Oct 26, 2017 23:39 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionRestricted Stock Units · Derivative | 7,953 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-058085 · doc4.xml · derivative · entry 3 Happel David · CIK 0001623567 · EVP, Commercial Dev & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,860 Underlying: Ordinary Shares · 7,953 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: On October 25, 2016, the reporting person was granted an aggregate of 31,813 restricted stock units. The restricted stock units vest in four equal annual installments beginning on October 25, 2017. F3 · derivative.expiration_date: On October 25, 2016, the reporting person was granted an aggregate of 31,813 restricted stock units. The restricted stock units vest in four equal annual installments beginning on October 25, 2017. Read SEC document |
| October 25, 2017 Filed Oct 26, 2017 23:39 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Tax withholdingOrdinary Shares | 4,150 | $13.53 | $56,149.50 |
DisclosureSEC source: 0001209191-17-058085 · doc4.xml · nonDerivative · entry 2 Happel David · CIK 0001623567 · EVP, Commercial Dev & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,089 Read SEC document |
| October 25, 2017 Filed Oct 26, 2017 23:39 UTC | Horizon Therapeutics Public Ltd Co HZNP · Entity 109157 | Exercise / conversionOrdinary Shares | 7,953 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-058085 · doc4.xml · nonDerivative · entry 1 Happel David · CIK 0001623567 · EVP, Commercial Dev & Strategy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,239 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F2 · balance_after: Includes 1,286 ordinary shares of the Issuer acquired by the reporting person on June 1, 2017 pursuant to an employee stock purchase program. Read SEC document |
| October 25, 2016 Filed Oct 26, 2016 16:41 UTC | Raptor Pharmaceutical Corp RPTP · Entity 181476 | Disposition to issuerStock Option (right to buy) · Derivative | 93,784 | Not disclosed Strike: $3.74 | Not disclosed |
DisclosureSEC source: 0001140361-16-083653 · doc1.xml · derivative · entry 3 Happel David · CIK 0001623567 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 93,784 shares Expires 2026-02-09 F3 · price: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding stock option was accelerated in full and cancelled in exchange for the right to receive $9.00 in cash, without interest and less the exercise price of such option and any required withholding taxes. Read SEC document |
| October 25, 2016 Filed Oct 26, 2016 16:41 UTC | Raptor Pharmaceutical Corp RPTP · Entity 181476 | Disposition to issuerCommon Stock | 28,939 | $9.00 | $260,451.00 |
DisclosureSEC source: 0001140361-16-083653 · doc1.xml · nonDerivative · entry 2 Happel David · CIK 0001623567 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: Pursuant to the Merger Agreement, on October 25, 2016, each outstanding restricted stock unit was accelerated in full and cancelled in exchange for the right to receive $9.00 per share in cash, without interest and less any required withholding taxes. Read SEC document |
| October 24, 2016 Filed Oct 26, 2016 16:41 UTC | Raptor Pharmaceutical Corp RPTP · Entity 181476 | OtherCommon Stock | 8,934 | $9.00 | $80,406.00 |
DisclosureSEC source: 0001140361-16-083653 · doc1.xml · nonDerivative · entry 1 Happel David · CIK 0001623567 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,939 F1 · kind: Shares tendered in connection with an offer to purchase all of the issued and outstanding shares of common stock of Raptor Pharmaceutical Corp. ("Raptor"), par value $0.001 per share, for an amount of $9.00 per share in cash, without interest and less any applicable withholding taxes, commenced pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of September 12, 2016, by and among Raptor, Horizon Pharma plc, a public limited company organized under the laws of Ireland ("Parent") and Misneach Corporation, a Delaware corporation and an indirect wholly owned subsidiary of Parent. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.